Chiropractors in Beach, ND Accepting Medicare
3 Chiropractors found. Showing 1 - 3
 Mrs. Kylie Brook Simnioniw, D.C. Chiropractor Medicare: Not Enrolled in Medicare Practice Location: 110 S Central Ave, Beach, ND 58621 Phone: 701-872-7520 Fax: 701-872-7521 |
 Holkup Chiropractic Clinic Pc Chiropractor Medicare: Medicare Enrolled Practice Location: 110 S Central Ave, Beach, ND 58621 Phone: 701-872-7520 Fax: 701-872-7521 |
 Dr. Jacob P Holkup, DC Chiropractor Medicare: Accepting Medicare Assignments Practice Location: 110 S Central Ave, Beach, ND 58621 Phone: 701-872-7520 Fax: 701-872-7521 |
News Archive
Researcher uses gold nanoparticles and lasers to target bladder cancer
A University of Colorado Cancer Center study takes a new approach to killing cancer: Why not fry it into oblivion with vibrating gold nanoparticles? "But what about the frickin' lasers?" you may ask. Don't worry. There are lasers. And bioluminescence too.
SIS files a patent aplication for a method of generating structured light for 3D image rendering
Spatial Integrated Systems, Inc. ("SIS"), a leader in the development and integration of solutions incorporating next-generation digital 3D data capture and processing technologies, announced today that a United States patent application has been published for "system and method for generating structured light for 3-dimensional image rendering" under Publication No. US2009/0169095A1.
Recommendations to help ensure access to high-quality opioid use disorder treatment
On January 14, 2021, the Department of Health and Human Services (HHS) submitted notice to the Federal Register that it would issue practice guidelines that exempt physicians from the requirement to apply for a waiver to prescribe buprenorphine to treat opioid use disorder (OUD) in up to 30 patients at one time.
Promising results from Soligenix' RiVax vaccine against ricin toxin
Soligenix, Inc., formerly known as DOR BioPharma, Inc., a late-stage biotechnology company, announced today the publication of an article in the January 2010 edition of Infection and Immunity, detailing the characteristics of several immunodominant regions of ricin A chain, the antigenic component of RiVax((TM)). RiVax((TM)) is Soligenix's vaccine to protect against exposure to ricin toxin and is currently being evaluated in Phase 1 human safety and immunogenicity trials, as well as nonhuman primate trials for efficacy.
Major Chinese breakthrough for pSivida - patent granted
This first patent grant in China is important as China has the highest incidence of primary liver cancer in the world with 345,844 cases in 2002 and is a logical target market for BrachySil. The potential lower cost of the Chinese registration pathway and the vast need of BrachySil like products make China an important commercial target.
› Verified 1 days ago